	US 11,702,459 B2
	MR1 restricted T cell receptors for cancer immunotherapy
Gennaro De Libero, Bottmingen (CH); Marco Lepore, Abingdon (GB); and Lucia Mori, Bottmingen (CH)
Assigned to UNIVERSITÄT BASEL, Basel (CH)
Filed by UNIVERSITÄT BASEL, Basel (CH)
Filed on Sep. 9, 2019, as Appl. No. 16/563,987.
Application 16/563,987 is a continuation in part of application No. PCT/EP2018/055620, filed on Mar. 7, 2018.
Claims priority of application No. 17159754 (EP), filed on Mar. 7, 2017; application No. 17179309 (EP), filed on Jul. 3, 2017; and application No. 18194025 (EP), filed on Sep. 12, 2018.
Prior Publication US 2019/0389926 A1, Dec. 26, 2019
Int. Cl. C07K 14/725 (2006.01); C12N 5/0783 (2010.01); G01N 1/30 (2006.01); G01N 33/569 (2006.01); C12N 5/09 (2010.01); C12N 15/85 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0693 (2013.01); C12N 15/85 (2013.01); G01N 1/30 (2013.01); G01N 33/56966 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/30 (2013.01)]

16 Claims

1. A method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule, said method comprising the steps of

a. providing a preparation of T cells, then

b. contacting said preparation of T cells with a cancer cell expressing MR1 in a contacting step, then

c. isolating a T cell that is specifically reactive to said cancer cell in an isolation step.